drugset / Trial / NCT04228315

Biomarkers of P. Vivax Relapse

NCT04228315

RandomizedParallel-groupOpen-labelTreatment

Summary

Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode of malaria illness (relapse). This clinical trial aims to enroll patient with P. vivax infections and try to detect signals in blood, urine and/or saliva coming from the silent liver stages to help identify who could benefit from treatment with primaquine. It also will explore if certain factors of patients negatively impact primaquine efficacy.

Timeline

Start
2019-11-19
Primary completion
2021-06-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Primaquine Small molecule 15 mg Oral